The Latest Breaking News on Mental health

The Food and Drug Administration granted accelerated approval of a disease-modifying treatment that could potentially give some patients with Alzheimer's disease something they haven't had before: a medication that may slow the decline of memory and thinking.

The wording of a letter informing patients their mental health service is in crisis is "a template, in case it's needed in the future", Tasmania's health department says — but a health union says it shows mental health care is "in such a state it might be embarrassing to admit".

Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until…

One in four sufferers commonly go two years undiagnosed, one study claims

Sometimes ADHD is not recognised when someone was a child, and they are diagnosed later as an adult

Students are more stressed than ever — and the best (and most obvious) solution is hiring enough school counselors

Opinion: Lifestyle interventions like social ballroom dancing are a promising, noninvasive, and cost-effective path toward staving off dementia as we – eventually – leave the Covid-19 pandemic behind.

Early intervention could reduce your risk of developing dementia-related disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

Parkinson's is a degenerative, neurological condition with no cure

The FDA on Friday authorized the use of the Alzheimer’s drug lecanemab, the first drug clearly shown to slow the progress of the debilitating brain disease.